40th Annual Feldman Lecture

October 3, 2025 | IN-PERSON EVENT

Delta Hotels – Edmonton South Conference Center

Top of the Inn, 4404 Gateway Boulevard NW, Edmonton AB

Guy Goodwin FMedSci, DPhil

Mood Disorder: From the Mundane Standard of Care to Novel Futuristic Approaches

Registration coming soonLearn More
PROFESSOR MARK EDWARDS

Dr Guy Goodwin, FMedSci, serves as the Chief Medical Officer at COMPASS Pathways. He is also an Emeritus Professor of Psychiatry at the University of Oxford, where he earned both his medical degree and DPhil in neurophysiology. After completing his psychiatry training, he worked as a Clinical Scientist and Consultant Psychiatrist at the MRC Brain Metabolism Unit at the Royal Edinburgh Hospital.

His research has focused on treating bipolar disorder and leveraging neuroscience to understand the neurobiology of mood disorders, aiming to develop innovative treatments. Currently, he is exploring the transformative potential of new technologies and drugs, particularly through the psychedelic experience.

He is a fellow of the American College of Neuropsychopharmacology and has previously served as President of both the British Association for Psychopharmacology and the European College of Neuropsychopharmacology (ECNP).

Plenary Sessions:

Plenary 1

The Challenge of Diagnosing, Stratifying and Treating Mood Disorder

In this talk, Professor Goodwin will discuss how current diagnostics and treatments for mood disorders have limitations, but evidence supports their efficacy, with ECT being notably effective, while serotonin’s role in depression is debated, and the potential of a genetic map for psychiatry is explored.

 

Plenary 2

Is Precision Psychiatry Possible for Management of Mood Disorder?

Professor Goodwin will describe how the efficacy of antidepressants is supported by clinical evidence, but subjective scales and placebo effects complicate psychiatric trials, highlighting the value of remote symptom monitoring and the growing impact of neuroscience and brain imaging on mood disorder management.

Plenary 3

Neuroplasticity or Profound Experience? Do Psychedelics Offer a Novel Approach?

Professor Goodwin will associate an exploration of psychedelics’ history and future, with evidence for rapid-acting depression treatments, consider controversies in trial methodologies, and the potential integration of interventional psychiatry with established psychotherapies.

|

“Patients with treatment-resistant depression have greater severity and duration of illness, disability, physical illness, incidences of hospitalization, risk of suicide, and economic costs than patients with treatment-responsive depression. Psilocybin may offer treatment alternatives.”

Overall Learning Objectives

Upon completion of this conference, participants should be able to:

  • Evaluate current diagnostics and treatments for mood disorders, including their limitations, efficacy, and the role of serotonin and genetics.
  • Assess the potential of precision psychiatry through evidence supporting antidepressants, challenges in clinical trials, and advancements in remote monitoring and neuroscience.
  • Explore innovative approaches in psychiatry, focusing on the history and future of psychedelics, rapid-acting treatments, trial methodologies, and the integration of interventional psychiatry with psychotherapies.

 

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. You may claim a maximum of 3.5 hours (credits are automatically calculated).

Agenda

October 3, 2025
8:00 am Mountain Time
In-person Event
Delta Hotel – Edmonton South Conference Centre

Time Event
08:00 – 09:00 Registration and Continental Breakfast
09:00 – 09:10 Tribute to Zane Feldman
Welcome and Introduction of Honored Speaker
09:10 – 10:00 Plenary 1 – The Challenge of Diagnosing, Stratifying and Treating Mood Disorder
10:00 – 10:20 Question and Answer Period
10:20 – 10:50 Health Break
10:50 – 11:40 Plenary 2 – Is Precision Psychiatry Possible for the Management of Mood Disorders?
11:40 – 12:00 Question and Answer Period
12:00 – 13:15 Lunch
13:15 – 14:05 Plenary 3 –Neuroplasticity or Profound Experience? Do Psychedelics Offer a Novel Approach?
14:05 – 14:25 Question and Answer Period
14:25 – 15:00 Plenary 4 – Expert Panel Discussion
15:00 Closing Remarks

Zane Feldman

Zane Feldman made a significant donation to the Department of Psychiatry at the Edmonton General Hospital (now the Grey Nuns Community Hospital) in 1981 in gratitude for the care extended to his two sons. This donation created The Feldman Lectures which began in 1983.

Mr. Feldman was born in Winnipeg in 1923, the son of Israel and Rose (Frank) Feldman. He served in the RCAF and moved to Edmonton in 1949. He had a taxi business before becoming a partner in Crosstown Motor City and later President of West Edmonton Chrysler. Active in the sports community, Zane Feldman was President of the Edmonton Oil Kings and founder and governor of the original Edmonton Oilers in the WHA. He was a director of the Alberta Cancer Board for two years and played a key role in the acquisition of the land for the new Beth Israel Synagogue in West Edmonton. He was the recipient of the Order of Canada Medal in 1992 and was the Negev Dinner honoree in 1993.  Mr. Feldman died in 2003 at the age of 80.

Past Feldman Lecture Distinguished Presenters

1983-2022

1983
Dr. Paul E. Garfinkel, M.D., F.R.C.P. (C)

Professor and Vice Chairman, Department of Psychiatry, University of Toronto
"Selecting an Antidepressant"

 

1984
Dr. Heinz Lehmann

Professor Emeritus, Department of Psychiatry
McGill University Montreal
"Schizophrenia - Psychiatry's Evergrowing Problem"

 

1985
Dr. David Sheehan

University of South Florida, Tampa, Florida
"The Anxiety Disease", "The Biology of Panic"

1986
Dr. Hagop S. Akiskal, M.D.

Professor of Psychiatry, The University of Tennessee, Memphis
"Interaction of Psychologic and Biologic factors in the Origin of Mood Disorders", 
"The Soft Bipolar Spectrum - Clinical and Social Significance"

1987
Cancelled

 

 

1988
Dr. Harold Mersky

Professor of Psychiatry, University of Western Ontario, Director of Education and Research, London Psychiatric Hospital

"The Idea of Hysteria" "Pain and Compensation" "An individual Perspective on the abuses of Psychiatry in the USSR" "Psychological aspects of Pain"

1989
Professor Sir Martin Roth

University of Cambridge, Department of Psychiatry, Adenbrooke's Hospital, Cambridge, England

"Some Contemporary Growing Points in the Study of Alzheimer's Disease" "Travelling Between Doubt and Certainty in Medicine and Elsewhere" "Use and Abuse of Benzodiazepines"

1990
Norman E. Rosenthal, M.D.

Chief, Unit of Outpatient Studies, Clinical Psychobiology Branch, National Institute of Mental Health, Bethesda, Maryland

"Epidemiologic and Seasonal Changes in the General Population" " What We Know about the Physiological Underpinnings of Seasonal Changes" "Diagnosis of SAD and all its Variants" "Treatment of Seasonal Affective Disorder - Light and Beyond"

1991
Dr. Marie Asberg

Karolinska Institute, Department of Psychiatry and Psychology, Karolinska Hospital, Stockholm, Sweden

"Psychobiology and suicide - can we close the gap between Psychodynamic and Biological Models?"

1992
Dr. Bessel A. van der Kolk

Chief, Erich Linderman Mental Health Centre Trauma Clinic, Massachusetts General Hospital, Harvard Medical School

"Dissociation, Trauma and Psychiatric Illness"

1993
Dr. C.B. Nemeroff

Head, Department of Psychiatry & Behavioural Sciences, Emory University, Atlanta, Georgia

The Biology, Diagnosis & Treatment of Affective Disorder

1994
Dr. Robert M. Post

Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland

Affective Disorders

1995
Dr. Sheldon Preskorn

Department of Psychiatry, University of Kansas School of Medicine, Psychiatric Research Institute, St. Francis Regional Medical Centre
Wichita, Kansas

Update on Antidepressants

1996
Dr. Philip Seeman

Department of Psychiatry, University of Toronto

Schizophrenia and dopamine receptors; Atypical antipsychotic drugs; Future Research and medications

1997
Dr. Norman Sartorius

President, World Psychiatric Association
Head, Mental Health Division, WHO (1997-1993)

“Mental Health and Primary Health Care”, “The Current State of Psychiatry”, “Comorbidity in Psychiatry”

1998
Dr. Glen Gabbard

Bessie Walker Callaway Distinguished Professor of Psychoanalysis and Education, Karl Menninger School of Psychiatry and Mental Health Sciences. The Menninger Clinic, Topeka, Kansas

“Psychodynamic Therapy in a Era of Neuroscience”
“Treatment of Depression Comorbid with Personality Disorders”
“Psychotherapy of the Chronically Suicidal Borderline Patient”

1999
Dr. Michael F. Myers

Clinical Professor, Faculty of Medicine, UBC
St. Paul’s Hospital, Vancouver, B.C.

“Mental Health in Physicians and Allied Professionals”

2000
Dr. Heidi L. Heard

Behavioural Technology Training Group, University of Washington
Behavioral Research and Therapy Clinics, Department of Psychology Seattle, WA

“Dialectical Behaviour Therapy”

2001
Dr. Harold Sackheim

Chief, Department of Biological Psychiatry New York State Psychiatric Institute
New York

“Update on Electroconvulsive Therapy”

2002
Dr. Shitij Kapur

Chief, Department of Biological Psychiatry
New York State Psychiatric Institute, New York

“Linking biology, phenomenology, and Pharmacology in Schizophrenia”

2004
Dr. Roger D. Weiss

Associate Professor of Psychiatry, Harvard Medical School, Clinical Director, Alcohol and Drug Abuse, Program, McLean Hospital

"Treatment Strategies for Patients with Substance Abuse and Dual Diagnosis"

2005
Lt.-Gen. Romeo Dallaire

Meritorious Service Cross, Commander of the 1st Canadian Divisiono, Deputy-Commander of the Canadian Army.

“A Personal Experience with PTSD”

2006
Dr. John W. Newcomer

Professor of Psychiatry and Medicine at Washington University School of Medicine in St. Louis. Medical Director for the Center for Clinical Studies at Washington University

“Atypical Antipsychotics: Metabolic Effects”

2007
Christine A. Padesky, PhD

Distinguished Founding Fellow, Academy of Cognitive Therapy, Co-Founder Center for Cognitive Therapy

“A New Paradigm for Cognitive Therapy of Personality Disorders”

2008
Arthur Caplan, PhD

Emanuel & Robert Hart Professor of Bioethics, Chair of the Department of Medical Ethics and the Director of the Centre for Bioethics at the University of Pennsylvania – Philadelphia

“Is it Ethical to seek to enhance ourselves and our children using biomedical knowledge?”

2009
Dr. Kenneth Kendler

Director, Virginia Institute for Psychiatric and Behavioral Genetics.

“Psychiatric Genetics: A Current Perspective”.

2010
Dr. Martin Seligman

Fox Leadership Professor at the University of Pennsylvania,, Philadelphia, Pennsylvania.

“The Nature & Science of Happiness”

2011
Dr. Arya Sharma

Professor of Medicine & Chair for Cardiovascular Obesity Research and Management, University of Alberta

"Obesity – Assessment & Treatment"

2012
Stephen Michael Stahl, M.D., Ph.D.

Department Of Psychiatry, University Of California – San Diego

“Neuropsychopharmacology of Atypicals”

2013
Baroness Susan Greenfield B.A. (Hons); M.A.; D. Phil

Oxford University, United Kingdom

"Are Digital Technologies Impacting on Wellness of Young Minds”

2014
Kay Redfield Jamieson, PhD

Professor of Medicine, Johns Hopkins University School of Medicine Baltimore, Maryland
"An Overview of Mood Disorders & Suicide"

2015
Jeffrey Lieberman, MD

Lawrence C. Kolb Professor & Chairman, Psychiatry, Columbia University Medical Centre - New York
"Schizophrenia: Past, Present & Future"
"Shrinks - The Untold Story of Psychiatry"

2016
David Nutt, MD

Edmond J. Safra Chair, Psychopharmacology Imperial College, London, England
"Research of Drugs that Affect the Brain & Conditions such as: Addictions, Anxiety & Sleep"

2017
Philip Cowen, BSc, MB, BS, MD, FRCPSYCH

Professor, Psychopharmacology - University of Oxford, Oxford, England, United Kingdom
Classification of Depression & Implications for Treatment

2018
Laurence J. Kirmayer, MD FRCPC FCAHS, FRSC

James McGill Professor & Director, Division of Social & Transcultural Psychiatry, McGill University - Montreal, Quebec
"Integrating Culture & Context in Theory & Practice in Psychiatry"

2019
Dr. Judy Cameron, PhD. University of Pittsburg
Dr. George Koob PhD. Bethesda, MD
Dr. Stephanie Covington PhD, LCWS, La Jolla, California

"The Brain Story"

2020
Cancelled
2021
Cancelled
2022
Professor Mark Edwards MBBS, BSc (Hons), PhD, FRCP, FEAN

King’s College, London, UK
“Functional Neurological Disorders”

2023
Professor Anna Lemke MD

Stanford University School of Medicine
“Dopamine Nation: Finding Balance in the Age of Indulgence”

2024
Professor Oliver Howes BM, BCh, MA, MRCPsych, PhD, DM, FMedSci

King’s and Imperial Colleges, London, UK
“Schizophrenia: From Molecule to Management”